Adma Biologics (ADMA) Misses Q2 EPS by 8c

Adma Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.44), $0.08 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.3 million, versus $1.5 million reported last year.

For earnings history and earnings-related data on Adma Biologics (ADMA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline